Cortechs.ai develops and markets cutting-edge imaging solutions that are used by radiologists, neurologists, and oncologists in hundreds of clinics and research centers around the world. The Cortechs.ai team includes scientists, engineers, business professionals, and clinical specialists working towards the common goal of improving the diagnosis and treatment of patients with neurodegenerative disorders and cancers.

Cortechs.ai's​ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.